Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 900 Middlesex Turnpike BILLERICA MA 01821 |
Tel: | N/A |
Website: | https://www.quanterix.com |
IR: | See website |
Key People | ||
Masoud Toloue President, Chief Executive Officer, Director | Vandana Sriram Chief Financial Officer |
Business Overview |
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms. |
Financial Overview |
For the fiscal year ended 31 December 2023, Quanterix Corp revenues increased 16% to $122.4M. Net loss decreased 67% to $32.3M. Revenues reflect Product revenue segment increase of 14% to $79.5M, Service and other revenue segment increase of 17% to $40.3M. Lower net loss reflects Interest Expense/Income - Net increase from $5.1M to $15.8M (income), Selling, General & Administrative Expens decrease of 3% to $77.1M (expense). |
Employees: | 441 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $294.45M as of Dec 31, 2023 |
Annual revenue (TTM): | $122.37M as of Dec 31, 2023 |
EBITDA (TTM): | -$41.80M as of Dec 31, 2023 |
Net annual income (TTM): | -$32.33M as of Dec 31, 2023 |
Free cash flow (TTM): | -$22.69M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 38,247,078 as of Apr 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |